On the "Gosuslug" portal, it became possible to specify data on a foreign passport so that this information was entered into the electronic certificate of the vaccinated.

This was announced by the deputy head of the department Oleg Kachanov.

“It should be borne in mind that the rules of international regulation and requirements for vaccination are still being formed so that Russians can use certificates from the State Services portal to travel abroad,” Kachanov said.

He recalled that during the period when the service was being tested, only the data of the passport of a citizen of the Russian Federation were used.

In this case, if the user of the "Gosuslug" service specifies the data of the passport after the completion of testing, then the certificate will be renewed automatically.

“We have launched the automatic generation of vaccination certificates in English on the government services portal.

The automatic procedure of transliteration on the portal has been agreed with the Ministry of Health of Russia and will be carried out in accordance with the rules of translation of the Ministry of Internal Affairs of Russia, which are applied when issuing a foreign passport of a citizen of the Russian Federation, ”the deputy head of the Ministry of Digital Science emphasized.

The vaccination certificate issuance service has been launched on the Gosuslug portal since January 2.

COVID-19 statistics

Over the past day, 8294 new cases of coronavirus have been detected in Russia.

9445 patients were discharged, 374 people died from complications that developed against the background of COVID-19 and concomitant diseases.

Thus, in the Russian Federation for the fourth day in a row, the daily increase in cases of coronavirus does not exceed 9 thousand.

The total number of cases of coronavirus infection recorded in the country since the beginning of the pandemic reached 4,606,162. 4,229,480 people recovered, 101,480 died.

The largest number of COVID-19 cases were registered in Moscow (1585), St. Petersburg (705) and the Moscow region (570).

  • AFP

  • © Yuri KADOBNOV

According to Rospotrebnadzor, over 122.3 million laboratory tests for coronavirus have been performed so far, including 249 thousand in the last 24 hours.

491 thousand people remain under medical supervision.

According to the chief physician of the Leader of Medicine medical center, pediatrician, infectious disease specialist Yevgeny Timakov, an increase in the incidence of coronavirus infection may occur in Russia in mid-April.

“People have not yet acquired (the immune layer) and have not yet adapted to the virus after the first (surge in incidence).

And a repeated surge in the incidence now in the spring is very possible, unfortunately, "he said on the air of the Russia 24 TV channel.

In turn, Sergei Voznesensky, Associate Professor of the Department of Infectious Diseases of the RUDN University, said that at the moment the incidence of COVID-19 in the Russian Federation is at a plateau, while at the end of the month a decrease in the daily number of cases can be expected with an increase in the rate of vaccination.

“It all depends on several factors.

The first and most important thing is whether there will be variability in the virus.

If we see that the new strains that have come to Russia will differ from the previous ones, if there are repeated cases of the disease, then in this case the prognosis is negative, ”RIA Novosti quotes him.

At the same time, the representative of the World Health Organization (WHO) in Russia, Melita Vujnovich, said that the likelihood of a third wave of COVID-19 in any country cannot be predicted.

“It is impossible to predict when the COVID-19 outbreak in each country will peak, and where and when cases can be expected to recur,” she said.

Vaccines

The WHO representative also expressed hope that Russian vaccines will be included in the system of the World Health Organization.

We are talking about "EpiVacCoron", developed by the State Scientific Center for Virology and Biotechnology "Vector", the drug "CoviVac" from the Federal Scientific Center for Research and Development of Immunobiological Preparations named after M.P.

Chumakov Russian Academy of Sciences and the world's first vaccine against COVID-19 "Sputnik V", created by specialists from the Gamaleya National Research Center for Epidemiology and Microbiology.

The latter, according to the Financial Times, will be subject to an ethical and scientific review by the European Medicines Agency (EMA) next week.

“I don’t know how much this is an integral part of the registration process.

If this is something extraordinary, then, probably, there should be some explanations.

Maybe this applies to all vaccines.

I just don’t know, so I can’t give a precise answer to this, ”said the press secretary of the Russian President Dmitry Peskov, answering a question from journalists about the FT publication.

A Kremlin spokesman also referred the matter to the Russian Direct Investment Fund.

“I think it would be better to ask RDIF, which is in direct contact and who took part in the preparation of all the necessary documents and data and information related to the registration process for this vaccine in the EU,” he explained.

Earlier, the director of the Gamaleya Research Center for Electrochemistry, Alexander Gintsburg, said that Brussels is in no hurry to admit Sputnik V to the European Union market, as they fear that the Russian vaccine may "push" analogs promoted by the European bureaucracy.

On March 4, the EMA Committee on Medicines for Medical Use began the procedure for the consistent examination of the registration dossier of the Russian vaccine.

In addition, the head of the Yekaterinburg Research Institute of Viral Infections "Vector" Alexander Semyonov said that "EpiVacCorona" is effective against the "British" and "South African" SARS-CoV-2 strain.

According to him, the drug will protect the vaccinated person from the disease for at least a year.

He also spoke about the results of vaccination of people over 60 years old.

“We understand that using a vaccine produces effective antibodies 94% of the time.

And in any case, it protects against severe development of infection, "- explained the representative of the" Vector "center.